Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2 - PubMed (original) (raw)
. 2001 Aug 1;98(3):705-13.
doi: 10.1182/blood.v98.3.705.
Affiliations
- PMID: 11468170
- DOI: 10.1182/blood.v98.3.705
Free article
Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2
J S Miller et al. Blood. 2001.
Free article
Abstract
The stage of progenitor maturation and factors that determine the fate and clonal acquisition of human natural killer (NK) cell receptors during development are unknown. To study human NK cell receptor ontogeny, umbilical cord blood CD34(+)/Lin(-)/CD38(-) cells were cultured with a murine fetal liver line (AFT024) and defined cytokines. In the absence of lymphocyte-stimulating cytokines or when contact with AFT024 was prohibited, NK cell progeny were killer immunoglobulinlike receptor (KIR) and CD94 lectin receptor negative. In contrast, efficient NK cell differentiation and receptor acquisition was dependent on direct contact of progenitors with AFT024 and the addition of interleukin-15 (IL-15) or IL-2 but not IL-7. To address the question of whether receptor acquisition was determined at the stem cell level, single CD34(+)/Lin(-)/CD38(-) progenitors were studied. More than 400 single cell progeny were analyzed from cultures containing IL-15 or IL-2 and NK cells were always polyclonal, suggesting that receptor fate is determined beyond an uncommitted progenitor and that receptor-negative NK cells acquire class I-recognizing receptors after lineage commitment. KIR2DL2/L3/S2 was expressed more than KIR2DL1/S1 or KIR3DL1, and NKG2A was the dominant CD94 receptor, independent of whether the stem cell source contained the respective major histocompatibility complex class I ligand, suggesting a nonrandom sequence of receptor acquisition. The conclusion is that NK receptor fate is determined after NK cell commitment, does not require stromal presentation of human class I alleles, and is clonally stable after expression but dynamic because new receptors are acquired over time. (Blood. 2001;98:705-713)
Similar articles
- Mouse fetal and embryonic liver cells differentiate human umbilical cord blood progenitors into CD56-negative natural killer cell precursors in the absence of interleukin-15.
McCullar V, Oostendorp R, Panoskaltsis-Mortari A, Yun G, Lutz CT, Wagner JE, Miller JS. McCullar V, et al. Exp Hematol. 2008 May;36(5):598-608. doi: 10.1016/j.exphem.2008.01.001. Epub 2008 Mar 4. Exp Hematol. 2008. PMID: 18295962 Free PMC article. - Clonal analysis of NK cell development from bone marrow progenitors in vitro: orderly acquisition of receptor gene expression.
Williams NS, Kubota A, Bennett M, Kumar V, Takei F. Williams NS, et al. Eur J Immunol. 2000 Jul;30(7):2074-82. doi: 10.1002/1521-4141(200007)30:7<2074::AID-IMMU2074>3.0.CO;2-#. Eur J Immunol. 2000. PMID: 10940897 - IL-21 induces both rapid maturation of human CD34+ cell precursors towards NK cells and acquisition of surface killer Ig-like receptors.
Sivori S, Cantoni C, Parolini S, Marcenaro E, Conte R, Moretta L, Moretta A. Sivori S, et al. Eur J Immunol. 2003 Dec;33(12):3439-47. doi: 10.1002/eji.200324533. Eur J Immunol. 2003. PMID: 14635054 - Natural killer cell recognition of HLA class I molecules.
Brooks AG, Boyington JC, Sun PD. Brooks AG, et al. Rev Immunogenet. 2000;2(3):433-48. Rev Immunogenet. 2000. PMID: 11256749 Review. - The CD94/NKG2C-type lectin receptor complex in recognition of HLA class I molecules.
López-Botet M, Carretero M, Bellón T, Pérez-Villar JJ, Llano M, Navarro F. López-Botet M, et al. Res Immunol. 1997 Mar-Apr;148(3):155-9. doi: 10.1016/s0923-2494(97)84217-4. Res Immunol. 1997. PMID: 9255866 Review. No abstract available.
Cited by
- GMP-compliant iPS cell lines show widespread plasticity in a new set of differentiation workflows for cell replacement and cancer immunotherapy.
Terheyden-Keighley D, Hühne M, Berger T, Hiller B, Martins S, Gamerschlag A, Sabour D, Meffert A, Kislat A, Slotta C, Hafezi F, Lichte J, Sudheer S, Tessmer K, Psathaki K, Ader M, Kogler G, Greber B. Terheyden-Keighley D, et al. Stem Cells Transl Med. 2024 Sep 10;13(9):898-911. doi: 10.1093/stcltm/szae047. Stem Cells Transl Med. 2024. PMID: 39042522 Free PMC article. - Dimerization of Transmembrane Proteins in Cancer Immunotherapy.
Li L, Li J. Li L, et al. Membranes (Basel). 2023 Mar 30;13(4):393. doi: 10.3390/membranes13040393. Membranes (Basel). 2023. PMID: 37103820 Free PMC article. Review. - A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic Syndrome.
Arellano-Ballestero H, Sabry M, Lowdell MW. Arellano-Ballestero H, et al. Cells. 2023 Feb 16;12(4):633. doi: 10.3390/cells12040633. Cells. 2023. PMID: 36831300 Free PMC article. Review. - Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes.
Kouroukli O, Symeonidis A, Foukas P, Maragkou MK, Kourea EP. Kouroukli O, et al. Cancers (Basel). 2022 Nov 17;14(22):5656. doi: 10.3390/cancers14225656. Cancers (Basel). 2022. PMID: 36428749 Free PMC article. Review. - Efficient In Vitro Generation of IL-22-Secreting ILC3 From CD34+ Hematopoietic Progenitors in a Human Mesenchymal Stem Cell Niche.
Bennstein SB, Weinhold S, Degistirici Ö, Oostendorp RAJ, Raba K, Kögler G, Meisel R, Walter L, Uhrberg M. Bennstein SB, et al. Front Immunol. 2021 Dec 24;12:797432. doi: 10.3389/fimmu.2021.797432. eCollection 2021. Front Immunol. 2021. PMID: 35003122 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous